Jennifer Campbell, APRN
Primary Care · Newport News, VANPI 1922515972
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (49.8%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. AbbVie accounts for 61.0% of it on its own, with 17 other manufacturers making up the rest. Reporting peaked in 2023 at $3,161 and has fallen 68.3% since, to $1,001 in 2025. Among primary care clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 111 payments — averaging $69.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$5K
- EMD Serono, Inc.$704
- Biogen$597
- AstraZeneca$284
- Argenx US, Inc.$224
- TG Therapeutics, Inc.$200
- plus $983 from 12 others
What the payments were for
- Speaking & faculty fees$3,76349%
- Travel & lodging$841%
- Food & beverage$3,82150%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 40 | $4,676 |
| EMD Serono, Inc. | 15 | $704 |
| Biogen | 26 | $597 |
| AstraZeneca(2 entities) | 4 | $284 |
| Argenx US, Inc. | 2 | $224 |
| TG Therapeutics, Inc. | 2 | $200 |
| Lundbeck LLC | 3 | $186 |
| Otsuka America Pharmaceutical, Inc. | 1 | $125 |
| Neurocrine Biosciences, Inc. | 1 | $124 |
| Lilly USA, LLC | 1 | $123 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $121 |
| Novartis | 3 | $99 |
| Teva Pharmaceuticals USA, Inc. | 4 | $73 |
| Pfizer | 3 | $60 |
| Amgen | 2 | $37 |
| GSK | 1 | $17 |
| Genentech USA, Inc. | 1 | $14 |
| Corium, LLC | 1 | $3 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,668 in reported general payments places this provider in the 95th percentile of 142 primary care providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Nurtec OdtRimegepant Sulfate | 77 | $141,301 |
| Kesimpta PenOfatumumab | 11 | $96,580 |
| QuliptaAtogepant | 17 | $18,270 |
| Ajovy AutoinjectorFremanezumab-Vfrm | 11 | $9,534 |
| Gabapentin | 247 | $4,437 |
| Duloxetine Hcl | 115 | $3,115 |
| Lacosamide | 28 | $2,813 |
| Levetiracetam | 130 | $2,801 |
| Memantine Hcl | 124 | $2,299 |
| Donepezil Hcl | 282 | $1,861 |
| Divalproex Sodium | 44 | $1,764 |
| Pregabalin | 53 | $1,611 |
| Carbamazepine ErCarbamazepine | 13 | $1,544 |
| Propranolol Hcl ErPropranolol Hcl | 33 | $1,518 |
| Levetiracetam ErLevetiracetam | 17 | $1,200 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerNurtec Odt | $60 | $141,30177 claims |
| AbbVieQulipta | $4,676 | $18,27017 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 142 primary care providers in Virginia.
Other primary care in Newport News
- Rebecca GrinsellRichmond$12K
- Tien MaAnnandale$7K
- Michael CogginAshland$7K
- Erin StewartFredericksburg$6K
- Lawanda WoodNorfolk$6K
- Sara WeaverDanville$5K
- Luis Rivera PenaFalls Church$4K
- Erika RobinsonFredericksburg$4K
- Haley SwansonVirginia Beach$4K
- Lisa LewisDanville$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.